Tuberculin Purified Protein Derivative
Phase 3Small molecule
Tuberculin Purified Protein Derivative is one of 65 small molecule programs targeting Leprosy. It is currently in Phase 3.
3
Indications
4
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Sovaldi
GileadPhase 3
Repatha
AmgenPhase 3
Farxiga
AstraZenecaPhase 3
Retrovir
BBp Consulting, Inc
Phase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Igpro20
CSL BehringPhase 3
BIC/FTC/TAF
Merck & Co.Phase 3
Tuberculin Purified Protein Derivative
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Pegifn/rbv
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunodeficiency1 trial
Leprosy1 trial
Leprosy Skin Test Antigens Trial
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00128193·260 enrolled
Immune Response1 trial
Common Wart1 trial
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
Unknown status·—·Phase 3·NCT04288817·40 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details